NUMB and adenomyosis: The identification of NUMB as a prognostic biomarker in endometrial cancer (HR = 0.42, 95% CI: 0.22–0.81) suggests that adenomyosis-associated NUMB alterations may confer protective effects against malignant transformation, which has immediate clinical relevance for risk stratification and surveillance strategies.